EcoDrugPlus

Receptor Tyrosine-Protein Kinase Erbb-2-Like

Ensembl ID : ENSAOCG00000005685
Gene Symbol: LOC111577732
3 Cross references
200 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3-Like

Ensembl ID : ENSAOCG00000013304
Gene Symbol: LOC111581826
3 Cross references
207 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-4-Like

Ensembl ID : ENSAOCG00000012564
Gene Symbol: LOC111571821
3 Cross references
242 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSAOCG00000021278
Gene Symbol: RPTOR
3 Cross references
214 Possible Orthologues:

Renin-Like

Ensembl ID : ENSAOCG00000017916
Gene Symbol: LOC111576838
3 Cross references
220 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSAOCG00000004906
Gene Symbol: RET
3 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Rxr-Alpha-A

Ensembl ID : ENSAOCG00000008638
Gene Symbol: LOC111563713
3 Cross references
231 Possible Orthologues:

Retinoic Acid Receptor Rxr-Beta-A-Like

Ensembl ID : ENSAOCG00000004653
Gene Symbol: LOC111588825
3 Cross references
211 Possible Orthologues:

Retinoic Acid Receptor Alpha

Ensembl ID : ENSAOCG00000000432
Gene Symbol: RARA
3 Cross references
331 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSAOCG00000013692
Gene Symbol: RARB
4 Cross references
394 Possible Orthologues:

Retinoic Acid Receptor Beta-Like

Ensembl ID : ENSAOCG00000000907
Gene Symbol: LOC111582285
2 Cross references
380 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSAOCG00000024160
Gene Symbol: RARG
4 Cross references
383 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).